{"id":62817,"date":"2026-03-20T01:02:33","date_gmt":"2026-03-20T00:02:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/"},"modified":"2026-03-20T01:02:33","modified_gmt":"2026-03-20T00:02:33","slug":"aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/","title":{"rendered":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray"},"content":{"rendered":"
\n

\nUse of Aptar Pharma\u2019s UDS Powder system supports the development of a next\u2011generation, virus\u2011agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections<\/i><\/p>\n

CRYSTAL LAKE, Ill,–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) Powder Nasal Spray System is being utilized in ENA Respiratory\u2019s Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies in supporting the development of novel, non-vaccine approaches to respiratory disease prevention.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nENA Respiratory, a clinical\u2011stage pharmaceutical company developing antiviral host defense enhancers intended to help minimize the impact of symptomatic viral respiratory infections, recently announced<\/a> the dosing of the first participants in its Phase II study of INNA\u2011051. The Phase II study is assessing the safety, tolerability and potential effectiveness of the company\u2019s once\u2011weekly nasal spray in adults at increased risk of exposure to viral respiratory infections. The community\u2011based study is designed to evaluate the potential of INNA-051 to help reduce the burden of symptomatic respiratory viral illness.<\/p>\n

\nAptar Pharma\u2019s UDS powder nasal delivery system<\/a> is designed to deliver a single, precise dose of dry powder with consistent intranasal performance, intended to support consistent administration in clinical development settings. The ready-to-use system is designed to be simple to operate and well suited for nasal powder formulations that may benefit from enhanced stability.<\/p>\n

\nThe nasal delivery system will be housed in Aptar CSP Technologies\u2019<\/a> innovative container closure system, featuring fully-integrated 3-Phase Activ-Polymer\u2122 technology designed to protect the powder formulation against moisture. The system was designed with internal features to prevent premature actuation from device insertion, removal, or dropping, supporting reliable patient access to the drug.<\/p>\n

\n\u201cAptar Pharma is proud to support ENA Respiratory in the clinical development of INNA-051 through the use of our UDS powder nasal delivery system,\u201d said Alex Theodorakis, President, Aptar Pharma Prescription. \u201cBy combining reliable intranasal delivery technologies with comprehensive technical and regulatory expertise, we help our partners advance innovative therapies intended to address unmet needs in respiratory health.\u201d<\/p>\n

\nAbout Aptar<\/b><\/p>\n

\nAptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world\u2019s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http:\/\/www.aptar.com<\/a>.<\/p>\n

\nAbout ENA Respiratory<\/b><\/p>\n

\nENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections through the development of host defence enhancers which locally prime and boost the body\u2019s natural first line of defence against invading pathogens. Being virus-agnostic, ENA\u2019s approach offers a solution to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist. For more information, please visit www.enarespiratory.com<\/a>.<\/p>\n

\nThis press release contains forward-looking statements, including regarding the use of Aptar Pharma\u2019s intranasal spray platform in third-party intranasal clinical development activities and the potential role of such platform in supporting pharmaceutical development programs. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cfuture,\u201d \u201cpotential,\u201d \u201ccontinues\u201d and other similar expressions or future or conditional verbs such as \u201cwill,\u201d \u201cshould,\u201d \u201cwould\u201d and \u201ccould\u201d are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:<\/i> risks related to clinical development activities conducted by third parties; development and commercialization risks; customer adoption; regulatory requirements and compliance; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nAptar Investors Relations Contact:<\/b>
Mary Skafidas
\n
mary.skafidas@aptar.com<\/a>
+1 347 351 6407<\/p>\n

\nAptar Pharma Media Contact:<\/b>
Ciara Jackson
\n
ciara.jackson@aptar.com<\/a>
+49 151 1951 6502<\/p>\n

\nAptar Media Contact:<\/b>
Katie Reardon
\n
katie.reardon@aptar.com<\/a>
+1 815 479 5671<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Use of Aptar Pharma\u2019s UDS Powder system supports the development of a next\u2011generation, virus\u2011agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections CRYSTAL LAKE, Ill,–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62817","6":"format-standard","7":"category-industry"},"yoast_head":"\nAptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Use of Aptar Pharma\u2019s UDS Powder system supports the development of a next\u2011generation, virus\u2011agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections CRYSTAL LAKE, Ill,–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T00:02:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray\",\"datePublished\":\"2026-03-20T00:02:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/\"},\"wordCount\":856,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260319657698\\\/en\\\/2752586\\\/22\\\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/\",\"name\":\"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260319657698\\\/en\\\/2752586\\\/22\\\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg\",\"datePublished\":\"2026-03-20T00:02:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260319657698\\\/en\\\/2752586\\\/22\\\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260319657698\\\/en\\\/2752586\\\/22\\\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/","og_locale":"en_US","og_type":"article","og_title":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend","og_description":"Use of Aptar Pharma\u2019s UDS Powder system supports the development of a next\u2011generation, virus\u2011agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections CRYSTAL LAKE, Ill,–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-20T00:02:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray","datePublished":"2026-03-20T00:02:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/"},"wordCount":856,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/","url":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/","name":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg","datePublished":"2026-03-20T00:02:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260319657698\/en\/2752586\/22\/Unidose-Powder-Nasal-Spray-device_Transparent.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aptars-unidose-powder-nasal-delivery-system-used-in-ena-respiratory-phase-ii-clinical-study-of-investigational-inna-051-nasal-spray\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aptar\u2019s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA\u2011051 Nasal Spray"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62817"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62817\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}